J Korean Diabetes.  2020 Sep;21(3):120-125. 10.4093/jkd.2020.21.3.120.

Management of Diabetes in Coronavirus Disease 2019: Prognosis and Practical Issues

• Kim HS

• KMID: 2507042
• DOI: http://doi.org/10.4093/jkd.2020.21.3.120

Abstract

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a global pandemic by the World Health Organization on March 11, 2020. COVID-19 pandemic emphasizes the importance of understanding the pathophysiology which can potentially influence the treatment choices of people with chronic disease such as type 2 diabetes. The reasons for worse prognosis with COVID-19 in people with diabetes include age, sex, ethnicity, comorbidities such as hypertension, cardiovascular disease, obesity and a proinflammatory status. Medications for glucose-lowering and antihypertensive agents should be carefully assessed which can modulate the risk or may have potential interactions with SARS-CoV-2. It is also important to note that SARS-CoV-2 may exacerbate glucose metabolism through direct beta-cell damage, leading to acute hyperglycemic complications and potential new onset diabetes.

Keyword

Coronavirus disease 2019; Severe acute respiratory syndrome coronavirus 2; Type 2 diabetes

Reference

1. World Health Organization. Coronav irus disease 2019 (COVID-19) situation report 186. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200724-covid-19-sitrep-186.pdf?sfvrsn=4da7b586_2 (updated 2020 Jul 24).

2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323:1239–42.

3. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 in patients in Wuhan. J Allergy Clin Immunol. 2020; 146:110–8.

4. COVID-19 National Emergency Response Center; Epidemiology and Case Management Team; Korea Centers for Disease Control and Prevention. Coronavirus disease-19: the first 7,755 cases in the Republic of Korea. Osong Public Health Res Perspect 2020;11:146. Osong Public Health Res Perspect. 2020; 11:146. Erratum for: Osong Public Health Res Perspect 2020;11:85-90.

5. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucoselowering medication. Diabetes Care. 2020; 43:1399–407.

6. Chung SM, Lee YY, Ha E, Yoon JS, Won KC, Lee HW, et al. The risk of diabetes on clinical outcomes in patients with coronavirus disease 2019: a retrospective cohort study. Diabetes Metab J. 2020; 44:405–13.

7. Cariou B, Hadjadj S, Wargny M, Pichelin M, AlSalameh A, Allix I, CORONADO investigators, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020; 63:1500–15.

8. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020; 31:1068–77.e3.

9. Sardu C, D'Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, et al. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care. 2020; 43:1408–15.

10. Maddaloni E, Buzzetti R. COVID-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev;2020; doi: 10.1002/dmrr.3321. [Epub ahead of print].

11. Rhee SY, Lee J, Nam H, Kyoung DS, Kim DJ. Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19. medRxiv. 20108555 [Preprint]. 2020 May 23. Available from: https://www.medrxiv.org/content/10.1101/2020.05.20.20108555v1.

12. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020; 323:1775–6.

13. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436:112–6.

14. Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. J Card Fail. 2020; 26:370.

15. Kim NY, Ha E, Moon JS, Lee YH, Choi EY. Acute hyperglycemic crises with coronavirus disease-19: case reports. Diabetes Metab J. 2020; 44:349–53.

16. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020; 8:546–50.

17. Cure E, Cumhur Cure M. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabetes Metab Syndr. 2020; 14:405–6.

18. Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Kissow H. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013; 154:4503–11.

19. Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013; 495:251–4.

20. Unübol M, Ayhan M, Guney E. Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis. J Clin Rheumatol. 2011; 17:46–7.

21. Chee YJ, Ng SJH, Yeoh E. Diabetic ketoacidosis precipitated by COVID-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract. 2020; 164:108166.

22. Suwanwongse K, Shabarek N. Newly diagnosed diabetes mellitus, DKA, and COVID-19: causality or coincidence? A report of three cases. J Med Virol;2020; doi: 10.1002/jmv.26339. [Epub ahead of print].

23. Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh RM Jr, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science;2020; doi: 10.1126/science.abd4251. [Epub ahead of print].